Financials data is unavailable for this security.
View more
Year on year Shandong Lukang Pharmaceutical Co Ltd grew revenues 9.34% from 5.62bn to 6.15bn while net income improved 78.37% from 138.01m to 246.17m.
| Gross margin | 24.06% |
|---|---|
| Net profit margin | 6.86% |
| Operating margin | 7.10% |
| Return on assets | 4.98% |
|---|---|
| Return on equity | 11.28% |
| Return on investment | 8.11% |
More ▼
Cash flow in CNYView more
In 2023, Shandong Lukang Pharmaceutical Co Ltd increased its cash reserves by 36.95%, or 143.01m. The company earned 604.01m from its operations for a Cash Flow Margin of 9.83%. In addition the company used 369.78m on investing activities and also paid 93.92m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.29 |
|---|---|
| Tangible book value per share | 3.36 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.20 |
|---|---|
| Quick ratio | 0.8253 |
| Total debt/total equity | 0.8308 |
|---|---|
| Total debt/total capital | 0.4452 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 63.64% and 79.93%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.78% |
|---|---|
| Div growth rate (5 year) | 23.94% |
| Payout ratio (TTM) | 23.77% |
| EPS growth(5 years) | 7.80 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 104.36 |
More ▼
